Affiliate Faculty
Guido Ferrari
(919) 684-2862
Summary
Dr. Ferrari is currently an Associate Research Professor in the Department of Surgery, Division of Surgical Sciences at Duke University Medical Center. He is directing the ELISPOT, CTL, and ADCC laboratories for the HVTN central laboratory at Duke. He has been serving as a WHO/UNAIDS Vaccine Initiative consultant for the past six years, and coordinated the organization of 5 international workshops for the transfer of ELISpot and ICS technologies to new laboratory sites involved in HIV vaccine studies.
Topics
Locations
Projects
Recent Publications
Wise, M. C., Xu, Z., Tello-Ruiz, E., Beck, C., Trautz, A., Patel, A., … Weiner, D. B. (2020). In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest. https://doi.org/10.1172/JCI132779
Giel-Moloney, M., Esteban, M., Oakes, B. H., Vaine, M., Asbach, B., Wagner, R., … Pugachev, K. V. (2019). Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. Sci Rep, 9(1), 20005. https://doi.org/10.1038/s41598-019-56550-4
Easterhoff, D., Pollara, J., Luo, K., Tolbert, W. D., Young, B., Mielke, D., … Ferrari, G. (2019). Boosting with AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency. J Virol. https://doi.org/10.1128/JVI.01120-19
Li, S. S., Gilbert, P. B., Carpp, L. N., Pyo, C.-W., Janes, H., Fong, Y., … Peng, X. (2019). Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. J Virol, 93(21). https://doi.org/10.1128/JVI.02041-18
Rouphael, N. G., Morgan, C., Li, S. S., Jensen, R., Sanchez, B., Karuna, S., … HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network, . (2019). DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest, 129(11), 4769–4785. https://doi.org/10.1172/JCI128699
Neidich, S. D., Fong, Y., Li, S. S., Geraghty, D. E., Williamson, B. D., Young, W. C., … Tomaras, G. D. (2019). Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J Clin Invest, 129(11), 4838–4849. https://doi.org/10.1172/JCI126391
Kibler, K. V., Asbach, B., Perdiguero, B., García-Arriaza, J., Yates, N. L., Parks, R., … Jacobs, B. L. (2019). Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC". J Virol, 93(21). https://doi.org/10.1128/JVI.00968-19
Pantaleo, G., Janes, H., Karuna, S., Grant, S., Ouedraogo, G. L., Allen, M., … NIAID HIV Vaccine Trials Network, . (2019). Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet Hiv, 6(11), e737–e749. https://doi.org/10.1016/S2352-3018(19)30262-0
Gray, G. E., Huang, Y., Grunenberg, N., Laher, F., Roux, S., Andersen-Nissen, E., … Corey, L. (2019). Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med, 11(510). https://doi.org/10.1126/scitranslmed.aax1880
Nyanhete, T. E., Frisbee, A. L., Bradley, T., Faison, W. J., Robins, E., Payne, T., … Tomaras, G. D. (2019). HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. Sci Rep, 9(1), 10165. https://doi.org/10.1038/s41598-019-46462-8
